Ouro Medicines
Series A in 2025
Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.
Timberlyne Therapeutics
Series A in 2025
Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.
Seek Pet
Private Equity Round in 2024
Seek Pet Foods is an OEM/ODM manufacturer specializing in the development and production of pet food and related products. The company utilizes advanced technologies, including American micropowder puffing and fresh meat emulsification, to create high-quality pet food. By incorporating locally sourced, ecological fresh chicken and duck meat, along with other essential nutrients, Seek Pet Foods aims to provide customers with natural and healthy options for their pets. The company focuses on delivering innovative and nutritious pet food solutions tailored to meet the needs of pet owners.
Positive Sequence Biology
Series A in 2024
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Shuaike Pet Food Products
Venture Round in 2024
Shuaike is a company specializing in pet supplies and food. The brand is derived from the English "seek", adheres to the brand management philosophy of "only natural fresh meat", and aims to make the best natural and healthy food for pets all over the world. American micro powder puffing technology and fresh meat emulsification technology, combined with local fresh chicken and duck meat, natural food, organic vegetables, fruits, and other nutrients to extract natural fresh meat pet food, now export dog food and cat food Shuikesaijia Natural cat and dog food.
Xiaohongshu
Secondary Market in 2024
Xiaohongshu, founded in 2013 and based in Shanghai, China, is a lifestyle sharing platform that allows users to share experiences through text, images, and videos. Initially aimed at assisting overseas travelers with shopping, it has transformed into a vibrant community focused on various lifestyle areas, including cosmetics, fashion, food, travel, entertainment, reading, fitness, and childcare. The platform serves as a social e-commerce space where users can post their favorite products, share shopping experiences, and discover global merchandise, particularly in luxury and beauty sectors. By fostering user-generated content, Xiaohongshu encourages a collaborative environment for lifestyle enthusiasts to exchange insights and recommendations.
GDS International
Post in 2024
GDS International portfolio currently comprises approximately 480 MW of data center capacity in service and under construction and an additional 590 MW held for future development across strategic locations in Hong Kong, Singapore, Malaysia (Johor), Indonesia (Batam), and Japan (Tokyo).
Chunqing Technology
Series A in 2024
Chunqing Technology is a company that create new generation of electric vehicles powered by alcohol and hydrogen. Chunqing Technology creates, manufactures, and distributes alcohol and hydrogen energy for the next generation of electric automobiles.
Tai Hydrogen Energy
Seed Round in 2024
Tai Hydrogen Energy is an energy solutions provider that focuses on the core products and application of clean energy based on green electricity and green hydrogen. It is a subsidiary of Chint Group.
Jingkong Energy
Series D in 2023
Jingkong Energy is an energy system research and development platform. They offer services for the development of smart power supply, electric power and energy storage, and fuel cell fields.
Doujin Culture
Seed Round in 2023
Doujin Culture is a cross-border e-commerce company that specializes in supporting brands seeking to expand their reach internationally. By providing a platform tailored for international users, Doujin Culture facilitates the promotion and sale of domestic brands in global markets. The company focuses on international trading, enabling clients to effectively market and distribute their products beyond local boundaries, thereby enhancing opportunities for growth and exposure in diverse consumer bases.
Quasar-Med
Acquisition in 2023
Quasar specializes in the manufacture of products for the medical device market, including catheters, electronics, and disposables. From initial design to mass production, Quasar’s integrative approach ensures superior outcomes, top quality, and cost-efficiency for clients. Founded in Hong Kong in 1988 by Boaz Amitai, the company was created to serve as a connection between its European, American, and Israeli customers and Chinese electronics manufacturers.
Farizon Auto, established in 2014 as part of Geely's New Energy Commercial Vehicles Group, is a pioneering brand in China's new energy commercial vehicle sector. The company has developed a comprehensive range of products, including heavy trucks, light trucks, small and mini trucks, light commercial vehicles, and buses, designed for various commercial applications. Farizon focuses on both urban and highway commercial vehicles, utilizing advanced technologies such as pure electric systems, range-extended electric power, liquid hydrogen, and methanol power. Supported by the largest new energy commercial vehicle research institute in China, Farizon employs over 2,000 engineers globally to drive its innovation. The company aims to lead a green commercial revolution by providing integrated services in intelligent green transportation and establishing a green energy supply network. Farizon is committed to achieving zero-carbon land transport in China, positioning itself as a comprehensive service provider for the full lifecycle of new energy commercial vehicles.
Tianbing Technology
Series C in 2023
Tianbing Technology is an advanced aerospace propulsion system supplier and aerospace vehicle provider. Tianbing Technology independently develops the next-generation ambient temperature green HCP liquid propellant and minimalist aerospace propulsion system. As an upgraded product of traditional chemical propulsion system, it can meet cost-effective aerospace. Advance system supporting needs. The next-generation green HCP aerospace propulsion system, first tested by Tianbing Technology, can be used in the small-vehicle main power and launch vehicle upper-level propulsion system.
Animoca Brands
Convertible Note in 2022
Animoca Brands, established in 2019 and headquartered in the Cayman Islands, is a venture capital firm focused on the technology sector. It invests in and supports creators who leverage web3 and blockchain technologies to drive digital property rights to gamers and internet users through non-fungible tokens (NFTs). The company develops and markets a portfolio of mobile applications, games, and educational products, utilizing gamification and blockchain to ensure transparency, security, and innovative business models.
Frontera Therapeutics
Series B in 2022
Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, dedicated to creating a low-cost and scalable platform for the development and production of high-quality recombinant AAV therapies. The company focuses on commercializing cost-effective gene therapies aimed at treating a range of genetic disorders, including those affecting ophthalmology, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has established a robust product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. Through its innovative approach, the company aims to improve patient outcomes by making genetic therapies more accessible and affordable in the global market.
Evat Master
Series A in 2022
Evat Master is a software-as-a-service (SaaS) platform designed to assist cross-border e-commerce businesses with their European VAT obligations. The company offers an online platform that enables users to efficiently manage and complete all required tax reporting procedures. By providing a streamlined solution for VAT declaration, Evat Master simplifies the tax reporting process for its clients, ensuring compliance with European regulations in an accessible manner.
Shuaike Pet Food Products
Private Equity Round in 2022
Shuaike is a company specializing in pet supplies and food. The brand is derived from the English "seek", adheres to the brand management philosophy of "only natural fresh meat", and aims to make the best natural and healthy food for pets all over the world. American micro powder puffing technology and fresh meat emulsification technology, combined with local fresh chicken and duck meat, natural food, organic vegetables, fruits, and other nutrients to extract natural fresh meat pet food, now export dog food and cat food Shuikesaijia Natural cat and dog food.
Hangzhou MoreSec Technology Co., Ltd. is a company based in Hangzhou, China, specializing in internet security software. It focuses on integrating threat intelligence and artificial intelligence technologies into enterprise security systems. MoreSec aims to provide comprehensive security solutions tailored for the cloud computing and Internet of Things (IoT) environments, addressing the evolving needs of businesses in safeguarding their digital assets.
ArriVent Biopharma
Series A in 2022
ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company aims to address unmet medical needs by identifying, developing, and commercializing differentiated medicines. ArriVent is advancing its lead development candidate, furmonertinib, alongside a pipeline of novel therapeutics, including next-generation antibody drug conjugates. The company's efforts are primarily centered on solid tumors, leveraging the team's extensive experience in drug development to enhance the potential of its therapeutic candidates from initial development through to approval and commercialization.
Recurrent.ai
Venture Round in 2021
Recurrent.ai is a Chinese company that specializes in AI-enabled corporate services aimed at enhancing sales efficiency. The company utilizes advanced machine learning technologies to analyze sales calls and conversations, transforming voice interactions into text for comprehensive analysis. Its offerings include a self-study engine for sales dialogue, which allows businesses to generate detailed big data dialogue analysis reports and maintain customer portrait records. By automating these processes, Recurrent.ai helps organizations reduce time and labor costs, improve sales conversion rates, and enhance overall decision-making capabilities.
Jinke Property Group Co., Ltd. is a prominent real estate development company based in Chongqing, China, established in 1994. The company focuses on developing residential, industrial, and commercial properties while also providing property management services for various types of buildings, including residential complexes, commercial centers, office structures, and hotels. In addition to its core real estate activities, Jinke is involved in generating wind power and operating hotels. The company offers a range of services such as asset management, industrial investment, and wealth management, along with specialized services in landscape design and architectural decoration. It aims to integrate eco-friendly practices into its projects, emphasizing the development of green residential areas and eco-cities. Jinke has cultivated a strong organizational culture that contributes to its ongoing growth and operational effectiveness.
Vision Medicals Technology
Series D in 2021
Vision Medicals Technology is a provider of advanced diagnostic services specializing in pathogenic gene detection. The company focuses on infection-precise medical treatment and employs high-throughput sequencing-based pathogen metagenomics, CRISPR-based rapid diagnosis, and other innovative technologies. By enhancing the detection capabilities for clinical pathogens, Vision Medicals aims to shorten reporting cycles and accelerate the development of the infection-accurate medical sector. It has developed proprietary pathogenic nucleic acid enrichment technology to detect micronucleic acids in clinical samples. The company leverages extensive big data in pathogen detection, supported by its genomics intelligent analysis and reporting system, to deliver precise and efficient medical diagnostics to its clients.
J&T Express
Private Equity Round in 2021
J&T Express is a logistics service provider founded in 2015 and headquartered in Jakarta, Indonesia. The company specializes in express delivery and courier services, primarily supporting the growth of the e-commerce sector. J&T Express operates in 13 countries across Southeast Asia, positioning itself as a leader in the region's express delivery market. By utilizing automated sorting warehouses in Indonesia and Singapore, J&T Express enhances operational efficiency and speed. The company caters to major e-commerce platforms, facilitating their expansion into new markets and contributing to the rapid development of its partners.
Positive Sequence Biology
Series A in 2021
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Edge Medical Robotics
Series C in 2021
Edge Medical Robotics, Inc. is a Shenzhen, China-based company that specializes in the design and development of advanced surgical equipment. Founded on May 4, 2017, the company is dedicated to researching and promoting cutting-edge smart technologies aimed at enhancing surgical safety and treatment efficacy. By focusing on the pursuit of excellence and refinement in its products, Edge Medical Robotics seeks to elevate health standards and improve overall social health outcomes.
Zeekr develops and manufactures premium electric vehicles and automobiles. It specializes in the fields of electronics, automotive and electric vehicles.
MediTrust Health
Series C in 2021
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.
Pulse is a health care service provider that assess coronary physiology and biomechanics through innovative techniques.
Pulse Medical Technology
Series C in 2021
Pulse Medical Technology develops innovative technology for the diagnosis and optimal treatment of pan-vascular diseases.
PolarisIC
Seed Round in 2021
PolarisIC specializes in the development of advanced measurement and imaging chip products, utilizing cutting-edge single-photon avalanche diode (SPAD) technology. The company offers two main product lines: direct photon time-of-flight (dToF) measurement chips and low-light imaging chips. The dToF chips are designed for various applications, including height determination for unmanned aerial vehicles (UAVs), obstacle avoidance, navigation for automated guided vehicles (AGVs), and smart perception in the Internet of Things (IoT). The low-light imaging chips boast high sensitivity and pixel digitization capabilities, with potential uses in night vision systems, security monitoring, industrial measurement, and smartphone photography. PolarisIC is committed to technological innovation, excelling in dToF detection, high-speed digital processing, detection algorithm fusion, and system integration.
ArriVent Biopharma
Series A in 2021
ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company aims to address unmet medical needs by identifying, developing, and commercializing differentiated medicines. ArriVent is advancing its lead development candidate, furmonertinib, alongside a pipeline of novel therapeutics, including next-generation antibody drug conjugates. The company's efforts are primarily centered on solid tumors, leveraging the team's extensive experience in drug development to enhance the potential of its therapeutic candidates from initial development through to approval and commercialization.
Launched in 2016, Soul App is now one of the leading social networking applications in China. With a robust user base among Chinese Gen Z, Soul was designed to empower self-value expression and foster genuine relationships based on interest graphs and AI algorithms. Soul aspires to build a virtual social playground for its users to socialize, connect and maintain relationships free from the geographic and social constraints. Soul is the first social networking platform in China that requires all users to interact through avatars, and has a unique business model driven by the integration of intensive user interactions and an engaging community. Soul distinguishes itself from other peers with focus on virtual identities, open-ended relationships based on interest graphs, extensive user generated content (UGC), decentralized content distribution and its proprietary technologies. Nowadays, Soul pioneers in embracing the AI technologies in the social networking industry to meet the evolving social demand from the younger generation. In 2020, Soul kicked off its AIGC technology R&D. In 2023, Soul launched a proprietary large language model (LLM), Soul X, and has seamlessly embedded AI capabilities across use cases on its platform, which epitomizes Soul's product philosophy of the “Synergic Model-application Interplay”.
J&T Express
Private Equity Round in 2021
J&T Express is a logistics service provider founded in 2015 and headquartered in Jakarta, Indonesia. The company specializes in express delivery and courier services, primarily supporting the growth of the e-commerce sector. J&T Express operates in 13 countries across Southeast Asia, positioning itself as a leader in the region's express delivery market. By utilizing automated sorting warehouses in Indonesia and Singapore, J&T Express enhances operational efficiency and speed. The company caters to major e-commerce platforms, facilitating their expansion into new markets and contributing to the rapid development of its partners.
Klook is a global online platform facilitating the booking of travel experiences, services, and accommodations. It offers a wide array of activities such as tours, theme park tickets, cultural experiences, and adventure activities across numerous destinations worldwide. Additionally, Klook provides essential travel services like public transport passes, airport transfers, car rentals, SIM cards/eSIMs, and dining reservations to cater to various aspects of travel planning.
Lalamove, originally launched as EasyVan in December 2013 in Hong Kong, is an on-demand logistics platform that connects customers with driver-partners for rapid delivery services. Operating in 21 markets across Asia and Latin America, the company serves over 7 million customers and boasts a network of more than 700,000 drivers. Lalamove has transformed traditional van hiring by enabling instant matches between customers and drivers, often within 12 seconds. The platform facilitates same-day deliveries, typically completing local deliveries within 55 minutes. Additionally, Lalamove provides features such as real-time vehicle tracking and driver ratings, allowing businesses to efficiently scale their delivery operations while optimizing drivers’ routes and earnings.
SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.
D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.
Yuanfudao
Series G in 2020
Yuanfudao, founded in 2012, is the largest online live course platform in China, catering to primary and secondary school students. With over 1 million paying users, it provides a comprehensive curriculum that includes subjects such as English, Mathematical Olympiad, and various all-subject courses for secondary education. The platform features live online tutoring conducted by nationally recognized teachers, allowing students to receive quality education from home. By utilizing big data analysis, Yuanfudao enables students to identify their learning weaknesses and engage in targeted learning, thus enhancing their educational outcomes. The combination of its extensive course offerings and a large pool of qualified educators benefits hundreds of thousands of students across the country.
Antengene
Series C in 2020
Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.
Yuanfudao
Series G in 2020
Yuanfudao, founded in 2012, is the largest online live course platform in China, catering to primary and secondary school students. With over 1 million paying users, it provides a comprehensive curriculum that includes subjects such as English, Mathematical Olympiad, and various all-subject courses for secondary education. The platform features live online tutoring conducted by nationally recognized teachers, allowing students to receive quality education from home. By utilizing big data analysis, Yuanfudao enables students to identify their learning weaknesses and engage in targeted learning, thus enhancing their educational outcomes. The combination of its extensive course offerings and a large pool of qualified educators benefits hundreds of thousands of students across the country.
Perfect Diary
Venture Round in 2020
Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum
Pinduoduo operates an e-commerce platform in China, allowing users to engage in group buying deals primarily through Tencent's WeChat app. Founded in 2015 and headquartered in Shanghai, Pinduoduo offers a diverse range of products including apparel, electronics, household goods, and food items. The platform aims to facilitate access to the digital economy for local communities and small businesses, enhancing productivity and creating new opportunities. Pinduoduo has developed a robust network of sourcing, logistics, and fulfillment capabilities to support its operations and improve customer experience.
Kuaishou Technology
Series F in 2019
Kuaishou Technology, founded in 2011 and based in Beijing, China, operates an online video and photo sharing application known as Kuaishou. The platform enables users to broadcast their daily activities and engage with a global audience through short videos, photos, and live streams. Kuaishou aims to enhance individual happiness by leveraging big data and artificial intelligence technology, promoting equal opportunities through its algorithms and ethical values. The app empowers everyday individuals in China to share their experiences and connect with fans worldwide. Additionally, Kuaishou has an international counterpart, Kwai, which offers similar features tailored for users outside of China. With an average of 275.9 million daily active users, Kuaishou generates revenue by selling virtual items, online marketing, and earning commissions from e-commerce transactions on its platform.
Chengjia Apartment
Series A in 2019
Chengjia Apartment is a rental start-up based in Shanghai, China, that offers a variety of accommodation options including apartments, hotels, and homestays. Founded in 2015, the company provides flexible rental terms ranging from weekly to long-term stays, catering to diverse customer needs. Chengjia Apartment focuses on creating a high-quality living environment, combining the comforts of home with hotel-style services to ensure a warm and comfortable experience for its guests. The business has expanded significantly, managing nearly 100 properties across major cities in China and offering over 10,000 houses and related services. Chengjia Apartment is jointly established by China Living Hotel Group and IDG Capital, reflecting a strong partnership in the hospitality sector.
Waterdrop
Series C in 2019
Waterdrop is a leading technology platform dedicated to insurance and healthcare service with a positive social impact. It's the largest independent third-party insurance platform in China in terms of life and health insurance first year premiums, distributed in 2020, according to iResearch. Through Waterdrop Insurance Marketplace and Medical Crowdfunding platforms, Waterdrop have built a massive social network of protection and support for people, raising awareness of insurance and ultimately providing insurance and healthcare service to consumers in China. It had listed on the New York Stock Exchange under the symbol “WDH” in May 2021.
Yimidida is an online logistics network platform based in Shanghai, China, founded in 2015. The company specializes in crowd-sourced delivery services, focusing on shipping products to rural towns across the country. Yimidida's logistics platform enhances the delivery process by offering features such as payment collection, transport insurance, return receipts, and delivery tracking. This comprehensive approach improves dispatch efficiency and optimizes truck deployment, ensuring that customers can receive their orders promptly, regardless of their location.
Antengene
Series B in 2019
Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.
NetEase Cloud Music
Series B in 2018
NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.
LianLian
Venture Round in 2018
Lianlian Yintong Electronic Payment Co., Ltd, commonly known as Lianlian Pay, was established in 2003 and has grown to become the fourth largest non-banking third-party payment service provider in China, with a registered capital of RMB325 million. The company specializes in offering payment, clearing, and value-added mobile payment services, boasting over 60 payment licenses across various countries and regions. Lianlian Pay facilitates cross-border payments for approximately 100 sites linked to nearly 50 cross-border e-commerce platforms, extending its services to more than 100 countries. With a commitment to providing convenient, safe, and efficient payment solutions, Lianlian has accumulated a client base of over 1.1 million cross-border e-commerce stores and has established a significant presence in the global payment landscape. Additionally, it became one of the inaugural partners in the China (Hangzhou) Cross-border E-commerce Comprehensive Pilot Area, which was the first national-level pilot zone approved by the Chinese government.
LianLian
Venture Round in 2018
Lianlian Yintong Electronic Payment Co., Ltd, commonly known as Lianlian Pay, was established in 2003 and has grown to become the fourth largest non-banking third-party payment service provider in China, with a registered capital of RMB325 million. The company specializes in offering payment, clearing, and value-added mobile payment services, boasting over 60 payment licenses across various countries and regions. Lianlian Pay facilitates cross-border payments for approximately 100 sites linked to nearly 50 cross-border e-commerce platforms, extending its services to more than 100 countries. With a commitment to providing convenient, safe, and efficient payment solutions, Lianlian has accumulated a client base of over 1.1 million cross-border e-commerce stores and has established a significant presence in the global payment landscape. Additionally, it became one of the inaugural partners in the China (Hangzhou) Cross-border E-commerce Comprehensive Pilot Area, which was the first national-level pilot zone approved by the Chinese government.
Klook is a global online platform facilitating the booking of travel experiences, services, and accommodations. It offers a wide array of activities such as tours, theme park tickets, cultural experiences, and adventure activities across numerous destinations worldwide. Additionally, Klook provides essential travel services like public transport passes, airport transfers, car rentals, SIM cards/eSIMs, and dining reservations to cater to various aspects of travel planning.
Curon Biopharma
Series A in 2018
Curon Biopharma is focused on developing drugs for immuno-oncology therapies. The company offers a range of innovative cancer immunotherapeutic agents aimed at overcoming the limitations of existing cancer treatment approaches. By providing advanced immunotherapies, Curon Biopharma enables physicians to enhance treatment options for their patients battling cancer.
Megvii, founded in 2011, is an artificial intelligence company that specializes in intelligent solutions and data services for enterprises and developers. The company is focused on its mission to create machines capable of seeing and thinking, leveraging its deep learning system, Brain++. Megvii aims to build a comprehensive AI engine that serves as the foundational technology for various applications. It connects standardized hardware, such as sensors and personal devices, with artificial intelligence and the Internet of Things (AIoT), commercializing three main application areas: Consumer IoT, City IoT, and Supply Chain IoT. By integrating hardware and software solutions, Megvii enables clients to efficiently establish AI infrastructure tailored to their needs, positioning itself as an expert in AIoT solutions.
Trax Technology Solutions Pte Ltd. specializes in providing in-store execution solutions, focusing on image recognition technology that transforms mobile images into actionable insights for the retail sector. Founded in 2010 and headquartered in Singapore, Trax serves tier-one manufacturers and channel partners both locally and internationally. Its innovative platform enables sales representatives to access detailed information about product availability, shelf share, pricing, and compliance swiftly through mobile devices. This technology enhances operational efficiency and effectiveness for consumer goods companies. Trax has established itself as a leader in computer vision solutions for the consumer packaged goods industry, partnering with various innovators in IoT technologies to capture retail realities. The company's clientele includes major global brands, and it operates offices across multiple regions, including APAC, Europe, the Middle East, North America, and South America.
Brii Biosciences
Venture Round in 2018
Brii Biosciences Limited is a biotechnology company focused on the research, development, and commercialization of innovative medicines for chronic and infectious diseases, including hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant infections. Founded in 2018, the company is headquartered in Durham, North Carolina, with additional offices in Shanghai, Beijing, and San Francisco. Brii Biosciences aims to enhance healthcare outcomes for patients in China by leveraging advanced technology and data. The company has established strategic partnerships with organizations such as AliHealth and Vir to further its mission. With a robust pipeline consisting of over 10 product candidates, Brii Biosciences is dedicated to addressing significant public health challenges both in China and globally, focusing on delivering better treatments and cures for life-threatening diseases.
China Chengxin Credit
Series A in 2018
China Chengxin Credit Co., Ltd. is a credit rating agency based in Beijing, China, with additional offices in Wuhan and Shanghai. Founded in 2005, the company offers a wide range of services related to credit information. These services include personal credit solutions such as credit reports, credit scores, credit monitoring, anti-fraud measures, and customized offerings. For corporate clients, the company provides credit reports, e-commerce certification, and pre-loan surveys for microfinance. China Chengxin Credit is also involved in social credit construction, assisting regional governments, industry platforms, enterprises, and institutions in developing and implementing comprehensive credit systems. Additionally, the company offers market research consulting, which encompasses industry reports and management consulting, further enhancing its value proposition in the fintech sector.
CStone Pharmaceuticals
Series B in 2018
CStone Pharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, focused on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment globally. Founded in 2015, the company has established a robust product pipeline that includes late-stage clinical candidates such as CS1001 and CS1003, which are monoclonal antibodies targeting programmed death ligands and receptors. Other notable products include ivosidenib, avapritinib, and Pralsetinib, which are designed to treat various cancers. CStone also develops additional candidates like CS1002, CS3002, CS3003, and Fisogatinib for solid tumors and liver cancer, respectively. The company has entered into strategic collaborations, including a licensing agreement with Numab Therapeutics AG for a tri-specific antibody and a clinical partnership with Bayer HealthCare to evaluate CS1001 in combination with other treatments. CStone Pharmaceuticals aims to meet the pressing medical needs of cancer patients through innovative therapies and has assembled a management team with extensive experience in drug development and commercialization.
Viela Bio
Series A in 2018
Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, which is expressed on various immune system B cells. This candidate is being developed for multiple indications, including neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. Additionally, Viela Bio is advancing VIB4920, aimed at preventing kidney transplant rejection and treating sjögren’s syndrome, as well as VIB7734, which targets cutaneous lupus erythematosus. The company has established a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several Asian markets. Founded in 2017, Viela Bio aims to address critical pathways underlying these diseases and improve patient outcomes globally.
Berry Oncology
Series A in 2018
Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.
LifeMine Therapeutics
Series A in 2017
LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.
iQIYI, Inc. is a prominent online entertainment platform in China, offering a wide range of services including internet video streaming, online gaming, live broadcasting, online literature, and e-commerce. Established in 2009 and headquartered in Beijing, the company operates under the iQIYI brand and has developed a comprehensive library of licensed and self-produced content across various genres such as movies, TV dramas, and animations. iQIYI generates revenue primarily through subscription services, boasting around 100 million paying subscribers and 500 million monthly active users. Additionally, the platform monetizes user-generated content through advertising, while also engaging in e-commerce via the iQIYI Mall, which specializes in entertainment-related merchandise. The company has diversified its offerings to include a live broadcasting service and a social media platform focused on entertainment. iQIYI faces competition from other streaming services such as Tencent Video and Alibaba's Youku, positioning itself as a leader in the rapidly evolving digital media landscape in China.
CStone Pharmaceuticals
Series A in 2016
CStone Pharmaceuticals is a clinical-stage biotechnology company based in Shanghai, China, focused on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment globally. Founded in 2015, the company has established a robust product pipeline that includes late-stage clinical candidates such as CS1001 and CS1003, which are monoclonal antibodies targeting programmed death ligands and receptors. Other notable products include ivosidenib, avapritinib, and Pralsetinib, which are designed to treat various cancers. CStone also develops additional candidates like CS1002, CS3002, CS3003, and Fisogatinib for solid tumors and liver cancer, respectively. The company has entered into strategic collaborations, including a licensing agreement with Numab Therapeutics AG for a tri-specific antibody and a clinical partnership with Bayer HealthCare to evaluate CS1001 in combination with other treatments. CStone Pharmaceuticals aims to meet the pressing medical needs of cancer patients through innovative therapies and has assembled a management team with extensive experience in drug development and commercialization.
COFCO is a leading supplier of agricultural products and services based in Beijing, China. The company operates across various sectors within the agricultural and food industry, focusing on the trade, processing, and distribution of commodities such as grain, edible oils, sugar, and cotton. COFCO plays a crucial role in connecting domestic markets with international suppliers, serving as a key channel for the import and export of bulk agricultural products like wheat, corn, rice, and sugar. The company is committed to utilizing renewable natural resources to provide healthy and nutritious food while enhancing living standards and social prosperity. In addition to its core activities, COFCO is involved in various sectors, including real estate, hospitality, non-grain bio-energy, packaging, and finance, thereby diversifying its business portfolio and contributing to economic growth.
LY.com allows users to search for places of interest at the local and city levels. LY.com pinpoints the right spots within a few clicks. Every place of interest comes with user reviews. If users are satisfied with the reviews, they can purchase tickets directly on the site. The company's goal is to become the leading service provider of leisure travel, making it easier for customers to enjoy travelling.
Berry Genomics
Series B in 2013
Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.
Alibaba Group
Private Equity Round in 2012
Alibaba Group is the largest online and mobile commerce company globally, primarily known for its extensive e-commerce platforms that connect buyers and sellers. It operates notable marketplaces in China, including Taobao, which focuses on consumer-to-consumer transactions, and Tmall, which caters to business-to-consumer interactions. The company's core business lies in its China commerce retail division, which is a significant source of cash flow. In addition to retail and wholesale transactions, Alibaba also generates revenue from various sectors, including international commerce, local consumer services, cloud computing, digital media and entertainment, and logistics through its Cainiao network. Alibaba's diverse portfolio positions it as a key player across multiple industries, including retail, logistics, and technology.